<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Compounds under development targeting alpha-synuclein</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Mechanism of action</th>
    <th align="left">Compound</th>
    <th align="left">Sponsor</th>
    <th align="left">Phase/status</th>
    <th align="left">
     <italic>N</italic> of patients
    </th>
    <th align="left">Recruited participants</th>
    <th align="left">RCT no.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Active immunization</td>
    <td align="left">PD01A, PD03A</td>
    <td align="left">AFFITOPE</td>
    <td align="left">Phase 1, completed</td>
    <td char="." align="char">36</td>
    <td align="left">PD</td>
    <td align="left">NCT02267434</td>
   </tr>
   <tr>
    <td align="left">Passive immunization</td>
    <td align="left">BIIB054 (SPARK Study)</td>
    <td align="left">Biogen</td>
    <td align="left">Phase 2, active, not recruiting, estimated completion 06-2021</td>
    <td char="." align="char">311</td>
    <td align="left">PD</td>
    <td align="left">NCT03318523</td>
   </tr>
   <tr>
    <td align="left">Passive immunization</td>
    <td align="left">Prasinezumab, PRX002/RO7046015 (PASADENA Study)</td>
    <td align="left">Prothena/Roche</td>
    <td align="left">Phase 2, active, not recruiting, estimated completion 02-2021</td>
    <td char="." align="char">316</td>
    <td align="left">PD</td>
    <td align="left">NCT03100149</td>
   </tr>
   <tr>
    <td align="left">Passive immunization</td>
    <td align="left">MEDI1341</td>
    <td align="left">AstraZeneca and Takeda</td>
    <td align="left">Phase 1, recruiting, estimated completion 01-2021</td>
    <td char="." align="char">48</td>
    <td align="left">healthy</td>
    <td align="left">NCT03272165</td>
   </tr>
   <tr>
    <td align="left">Passive immunization</td>
    <td align="left">Rec47</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">NPT200-11, NPT100-18A</td>
    <td align="left">Neuropore</td>
    <td align="left">Phase 1, completed</td>
    <td char="." align="char">55</td>
    <td align="left">Healthy</td>
    <td align="left">NCT02606682</td>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">NPT-088</td>
    <td align="left">Proclara (formerly Neurophage)</td>
    <td align="left">†</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">Anle138b [*]</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical, a clinical trial in PD is expected to begin end of 2020</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">CLR01 [*]</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">PBT434 [*]</td>
    <td align="left">Alterity Therapeutics Limited</td>
    <td align="left">Phase 1</td>
    <td char="." align="char">70</td>
    <td align="left">MSA</td>
    <td align="left">n.k.</td>
   </tr>
   <tr>
    <td align="left">α-syn aggregation inhibition</td>
    <td align="left">VX-765[*]</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">α-syn degradation enhancers</td>
    <td align="left">Rapamycin (Sirolimus)[*]</td>
    <td align="left">NYU Langone Health, NINDS</td>
    <td align="left">Phase 2, recruiting, estimated completion 08-2021</td>
    <td char="." align="char">56</td>
    <td align="left">MSA</td>
    <td align="left">NCT03589976</td>
   </tr>
   <tr>
    <td align="left">α-syn degradation enhancers</td>
    <td align="left">Micro-RNA-101 [*]</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">α-syn degradation enhancers</td>
    <td align="left">TLR4-agonist MPLA [*]</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">Nanobodies</td>
    <td align="left">VH14*PEST</td>
    <td align="left">n/a</td>
    <td align="left">Preclinical</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
   <tr>
    <td align="left">Epigenome editing</td>
    <td align="left">n/a</td>
    <td align="left">Duke University/Seelos Therapeutics</td>
    <td align="left">Phase 1</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">n/a</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>n/a = not applicable; n.k. = not known</p>
  <p>*Compounds primarily being tested in MSA</p>
  <p>
   <sup>†</sup>Trial completed in individuals with probable Alzheimer’s, may be applicable to synucleinopathies
  </p>
 </table-wrap-foot>
</table-wrap>
